The FDA's compounding advisory committee voted in July. If you sell, prescribe or advise on peptides, the boundaries of a compliant conversation have shifted, and getting them wrong is your license or your account. Protocol sheets, compliance guides and regulatory briefings, written for the people who have to answer the question in the room.
The April 15 Federal Register notice temporarily removed seven peptides from the Category 2 restricted list. That creates an ambiguous window — some pharmacies are compounding again, but formal rulemaking hasn't happened. Sales conversations require precision.
The peptide space is moving fast and the regulatory landscape is shifting weekly. Peptide Academy Professional gives practitioners and sales teams the clinical clarity to navigate it.
Understand your formulary at a mechanistic level. Know what you can say, what's restricted, and how to position compounds accurately to prescribers.
Read more →Rapid-reference protocol sheets for patient conversations. Mechanism, dosing ranges, contraindications, and current research — formatted for clinical use.
Read more →Adding peptide protocols to your menu? Get the clinical framework your staff needs to consult confidently, plus compliance guidance for your jurisdiction.
Read more →Stay ahead of what physicians are asking. Our regulatory briefings track FDA panel developments and compounding rule changes in plain language, in real time.
Read more →Evidence-based summaries on recovery and performance peptides, plus a per-compound anti-doping status table checked against the published WADA list. Anything not yet confirmed reads as unconfirmed, never as permitted.
Read more →Patients are coming in with questions about peptides they found online. Get the background to guide them to evidence-based decisions, not internet protocols.
Read more →Every resource is reviewed for accuracy, formatted for clinical utility, and updated when the regulatory landscape shifts.
One-page summaries for each compound: mechanism of action, indications researched, dosing ranges, administration routes, contraindications, drug interactions, and citation list. Formatted for clinical settings.
View sample →What you can and cannot say about each compound under current FDA compounding rules. Updated after every regulatory development. Includes the July 2026 panel impact analysis.
Read the guide →Plain-language briefings on every FDA compounding rule development. Understand the 503A/503B framework, Category 1 vs 2 status, and what each change means for your formulary or practice.
Latest briefing →How to discuss peptide protocols with prescribers accurately and within compliance boundaries. Includes common objections, evidence gaps to acknowledge, and appropriate clinical framing.
Read the framework →Every compound categorized by evidence quality: strong preclinical, emerging human data, or limited evidence. No overstating what the science shows. Essential for accurate clinical conversations.
View the breakdowns →Need to onboard a sales team or clinical staff? A team plan covers up to 10 people at one organization for $199 a month, managed from your account page. Larger rollouts and custom branded protocol sheets are quoted on request.
Contact us →All plans include access to the full consumer protocol library plus professional-tier resources. Cancel anytime.
Weekly regulatory updates and clinical notes for practitioners in the peptide space. Free. No spam.
Join practitioners and sales professionals already subscribed.
Protocol breakdowns, FDA regulatory updates, research summaries, and compliance news for practitioners — every day.
Follow @peptide_academy